Phenotypes and spontaneous cell cytotoxicity of mononuclear cells from patients with seronegative spondyloarthropathies: ankylosing spondylitis, psoriatic arthropathy and pauciarticular juvenile chronic arthritis--analysis of mononuclear cells from peripheral blood, synovial fluid and synovial membranes.
T-cell subpopulations and natural killer (NK) cells from peripheral blood, synovial fluid and synovial membranes from patients with seronegative spondyloarthropathies were investigated. Thirty-four patients with ankylosing spondylitis, sixteen patients with psoriatic arthropathy and six patients with pauciarticular juvenile chronic arthritis were studied. All the patient groups had normal proportions of T4+ and T8+ cells as well as normal T4/T8 ratios in peripheral blood. In the synovial fluids the T4/T8 ratios were reduced in ankylosing spondylitis and psoriatic arthropathy (p less than 0.05). Although both the T4 and T8 subpopulations were reduced, the T4/T8 ratios in the synovial membranes of patients with these two disorders tended to be within the normal range of that of peripheral blood. Increased numbers of T-cells in the synovial fluid from patients with ankylosing spondylitis expressed class II MHC antigens. The natural killer cell activity was normal in peripheral blood and synovial fluids of patients with ankylosing spondylitis and psoriatic arthropathy while it tended to be reduced, although not significantly, in pauciarticular juvenile chronic arthritis. Synovial membranes were almost devoid of NK cell activity. The number of Leu 7+ cells were reduced in synovial fluid of patients with psoriatic arthropathy (p less than 0.04), but not as significantly as in the two other patient groups.
Thoen
J
J
Institute of Immunology and Rheumatology, Rikshospitalet, Oslo, Norway.
Førre
O
O
Waalen
K
K
Pahle
J
J
D000328:Adult; D000906:Antibodies / Q000032:analysis; D001171:Arthritis, Juvenile / Q000473:pathology; D001769:Blood; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D007592:Joint Diseases / Q000276:immunology / Q000473:pathology* / Q000503:physiopathology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000502:physiology*; D007963:Leukocytes, Mononuclear / Q000145:classification / Q000502:physiology*; D008297:Male; D010641:Phenotype; D011565:Psoriasis / Q000473:pathology; D013167:Spondylitis, Ankylosing / Q000276:immunology / Q000473:pathology* / Q000503:physiopathology; D013582:Synovial Fluid / Q000166:cytology* / Q000502:physiology; D013583:Synovial Membrane / Q000473:pathology; D013601:T-Lymphocytes / Q000145:classification
D000906:Antibodies; D007370:Interferon Type I; D007376:Interleukin-2